FRASER F C
Can Med Assoc J. 1962 Sep 29;87(13):683-4.
The probability that a teratogen, applied to a pregnant mammal, will produce malformations in the embryo depends on the agent, the dose, the species, the genetic constitution of mother and embryo, and the developmental stage of the embryo. Several drugs (including salicylates and antibiotics) now being used in medical practice are teratogenic in experimental animals, some at doses comparable, on a body-weight basis, to those used therapeutically. Demonstration of teratogenicity in experimental animals can serve as a warning of possible teratogenic effects in man, and as a guide to the types of malformations the drug might produce, but failure to demonstrate teratogenic effects experimentally does not prove the drug's harmlessness to the human embryo. If thalidomide had produced only common malformations, such as cleft lip, its teratogenic nature might still be unrecognized. The final test must be careful follow-up of babies born to mothers who have taken the drug in question.
将致畸剂应用于怀孕的哺乳动物时,其在胚胎中产生畸形的可能性取决于该药剂、剂量、物种、母体和胚胎的基因构成以及胚胎的发育阶段。目前医疗实践中使用的几种药物(包括水杨酸盐和抗生素)在实验动物中具有致畸性,其中一些按体重计算的剂量与治疗剂量相当。在实验动物中证明致畸性可作为对人类可能产生致畸作用的警示,并可作为该药物可能产生的畸形类型的指南,但未能通过实验证明致畸作用并不能证明该药物对人类胚胎无害。如果沙利度胺仅产生常见的畸形,如唇裂,其致畸性质可能仍未被认识到。最终的检验必须是对服用相关药物的母亲所生婴儿进行仔细的随访。